> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Danaher's Tax Line Swung To A $75 Million Benefit As Diagnostics Margin Fell To 21.3%
- URL: https://www.bullished.co/danahers-tax-line-swung-to-a-75-million-benefit-as-diagnostics-margin-fell-to-21-3-227fe7ca/
- Published: 2026-10-21T11:01:20.000Z
- Updated: 2026-10-21T11:01:20.000Z
- Description: Released tax reserves drove third-quarter earnings per share to $1.71, while Diagnostics margin dropped after the Masimo deal.
- Author: Matteo Parrino
- Tags: Earnings, DHR, Industry: Healthcare

[Danaher](https://www.bullished.co/tag/dhr/) booked a $75 million income-tax benefit in the third quarter, against $168 million of tax expense a year earlier, after [net discrete tax benefits of $263 million](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000199/dhr-20260925.htm?ref=bullished.co) from released reserves pushed the effective tax rate to negative 6.6%, according to the company's 10-Q. Those settled audits, more than operations, explain the jump in earnings from continuing operations, while margins in the newly enlarged Diagnostics segment fell.

## The tax release behind the earnings jump

Earnings per diluted share from continuing operations were $1.71, [up from $1.27](https://www.marketwatch.com/story/danaher-3q-net-up-sharply-as-company-boosts-2026-adj-eps-view-b5338bc8?ref=bullished.co). The 10-Q says the $0.37 per share tax benefit, from reserves for uncertain tax positions released after audit settlements, and 2025 impairment charges drove the year-over-year increase.

Company-wide operating profit margin slipped to 19.0% from 19.1%. Adjusted earnings per share, the company's own measure, rose 11.5% to $2.11, according to the [earnings release](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000201/dhr-20261021xex991.htm?ref=bullished.co), which put revenue at $6.6 billion, up 8.5%.

Discontinued operations also carried a $28 million benefit from settled audits of earlier joint filings with Veralto and Fortive.

## Diagnostics: bigger, but thinner

Diagnostics sales rose 17.0%, primarily from the Masimo deal, but operating profit fell to $614 million from $665 million. Margin was 21.3%, against 27.0% a year earlier; the [prior quarter's filing](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000161/dhr-20260626.htm?ref=bullished.co) showed 16.9%.

The 10-Q lists the drags: acquired businesses' dilution cost 365 basis points (3.65 percentage points) and the Masimo inventory fair-value step-up cost 295, a charge of $84 million in the quarter. Core sales in the segment grew 0.5%, or 7.0% excluding respiratory testing.

Company-wide core sales rose 3.0%, or 5.5% excluding respiratory testing.

## A changed yardstick for core sales

Beginning with this report, core sales exclude tariff refunds passed on to customers, a change the company said last quarter it intended to make. Those refunds reduced reported sales by 1.0% in the quarter. The 10-Q says the boost to net earnings from the refunds, after customer payouts, was less than $100 million.

Masimo was bought on June 10 for about $9.8 billion in cash and financed partly with long-term debt and commercial paper. A Life Sciences acquisition added $37 million in upfront cash and $79 million deferred.

## Outlook

[Danaher raised full-year adjusted earnings per share guidance](https://www.marketwatch.com/story/danaher-3q-net-up-sharply-as-company-boosts-2026-adj-eps-view-b5338bc8?ref=bullished.co) to $8.57 to $8.62, from $8.45 to $8.60\. It expects fourth-quarter core revenue excluding respiratory to rise 4.0% to 5.0%, with respiratory a headwind of about 150 basis points. It expects an effective tax rate of about 17.0% for the year, and the filing flags a $185 million charge on canceled special equity awards in the fourth quarter.

The company's quarterly dividend of $0.40 per share is payable October 30, 2026 to holders of record on September 30.

### Sources

- [10-Q Filing — Danaher (DHR)](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000199/dhr-20260925.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Danaher (DHR), Q2 FY2026 filed 2026-07-21 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000161/dhr-20260626.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, dhr-20261021xex991.htm) — Danaher, filed 2026-10-21](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000201/dhr-20261021xex991.htm?ref=bullished.co) — SEC EDGAR
- [Danaher 3Q Net Up Sharply as Company Boosts 2026 Adj EPS View](https://www.marketwatch.com/story/danaher-3q-net-up-sharply-as-company-boosts-2026-adj-eps-view-b5338bc8?ref=bullished.co) — MarketWatch
- [Danaher: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/danaher-q3-earnings-snapshot-100912056.html?ref=bullished.co) — Associated Press
- [Danaher Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call](https://www.benzinga.com/analyst-stock-ratings/price-target/26/10/62435054/danaher-likely-to-report-higher-q3-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call?ref=bullished.co) — benzinga.com
- [Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?](https://finance.yahoo.com/markets/stocks/articles/danaher-gears-post-q3-earnings-124100275.html?ref=bullished.co) — Yahoo Finance
- [Danaher Sees Q4 2026 Non-GAAP Core Revenue Ex...](https://www.benzinga.com/news/26/10/62488717/danaher-sees-q4-2026-non-gaap-core-revenue-excluding-respiratory-revenue-4-5-yoy?ref=bullished.co) — benzinga.com

### More on Danaher

- [Danaher Lifts 2026 Adjusted EPS Outlook To $8.57-$8.62 As Core Growth Ex-Respiratory Hits 5.5%](https://www.bullished.co/danaher-lifts-2026-adjusted-eps-outlook-to-8-57-8-62-as-core-growth-ex-respiratory-hits-5-baa72797/)
- [Danaher Adds Former CFO Comas And Biotech Executive Hershberg, Lifting Board To 13 Seats](https://www.bullished.co/danaher-adds-former-cfo-comas-and-biotech-executive-hershberg-lifting-board-to-13-seats-4a509fa6/)

[All Danaher (DHR) coverage →](https://www.bullished.co/tag/dhr/)